Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 46:770-775, doi:10.1016/j.jacc.2005.05.060 (Published online 9 August 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fossum, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fossum, E.

The Effect of Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients With Hypertension Taking Aspirin

The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study

Eigil Fossum, MD, PhD*,*, Andreas Moan, MD, PhD{dagger}, Sverre E. Kjeldsen, MD, PhD*,{ddagger}, Richard B. Devereux, MD, FACC§, Stevo Julius, MD, ScD{ddagger}, Steven M. Snapinn, PhD||, Jonathan M. Edelman, MD||, Ulf de Faire, MD, PhD, Frej Fyhrquist, MD, PhD#, Hans Ibsen, MD, PhD**, Krister Kristianson, PhD{dagger}{dagger}, Ole Lederballe-Pedersen, MD, PhD{ddagger}{ddagger}, Lars H. Lindholm, MD, PhD§§, Markku S. Nieminen, MD, FACC#, Per Omvik, MD, PhD||||, Suzanne Oparil, MD, FACC¶¶, Hans Wedel, PhD##, Björn Dahlöf, MD, PhD*** for the LIFE Study Group

* Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
{dagger} MSD, Drammen, Norway
{ddagger} Department of Cardiology, University of Michigan, Ann Arbor, Michigan
§ Division of Cardiology, Cornell Medical Center, New York, New York
|| Merck and Co., Inc., Whitehouse Station, New Jersey
Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
# Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
** Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark
{dagger}{dagger} Merck Research Laboratories Scandinavia, Stockholm, Sweden
{ddagger}{ddagger} Department of Internal Medicine, Viborg Hospital, Viborg, Denmark
§§ Department of Family Medicine, Umeå University, Umeå, Sweden
|||| Department of Cardiology, Haukeland University Hospital, Bergen, Norway
¶¶ Department of Medicine, University of Alabama, Birmingham, Alabama
## The Nordic School of Public Health, Göteborg, Sweden
*** Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden



View larger version (31K):

[in a new window]
 
Figure 1 (A) Kaplan-Meier curves for the primary end point; p = 0.016 for aspirin interaction. (B) Kaplan-Meier curves for cardiovascular death. (C) Kaplan-Meier curves for stroke. (D) Kaplan-Meier curves for myocardial infarction; p = 0.037 for aspirin interaction.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement